Scholars@Duke

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.

Publication ,  Journal Article
Wierda, WG; Brown, J; Abramson, JS; Awan, F; Bilgrami, SF; Bociek, G; Brander, D; Chanan-Khan, AA; Coutre, SE; Davis, RS; Eradat, H; Hamid, MS ...
Published in: J Natl Compr Canc Netw
June 2022
Published version (DOI) Link to item

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.

Duke Scholars

Danielle Marie Brander
Author Danielle Marie Brander Medicine, Hematologic Malignancies and Cellular Therapy
Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2022.0031

EISSN

1540-1413

Publication Date

June 2022

Volume

20

Issue

6

Start / End Page

622 / 634

Location

United States

Related Subject Headings

  • Proto-Oncogene Proteins c-bcl-2
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Lymphoma, B-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Humans
  • Antineoplastic Agents
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wierda, W. G., Brown, J., Abramson, J. S., Awan, F., Bilgrami, S. F., Bociek, G., … Sundar, H. (2022). NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw, 20(6), 622–634. https://doi.org/10.6004/jnccn.2022.0031
Wierda, William G., Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, et al. “NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.” J Natl Compr Canc Netw 20, no. 6 (June 2022): 622–34. https://doi.org/10.6004/jnccn.2022.0031.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, et al. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jun;20(6):622–34.
Wierda, William G., et al. “NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.” J Natl Compr Canc Netw, vol. 20, no. 6, June 2022, pp. 622–34. Pubmed, doi:10.6004/jnccn.2022.0031.
Wierda WG, Brown J, Abramson JS, Awan F, Bilgrami SF, Bociek G, Brander D, Chanan-Khan AA, Coutre SE, Davis RS, Eradat H, Fletcher CD, Gaballa S, Ghobadi A, Hamid MS, Hernandez-Ilizaliturri F, Hill B, Kaesberg P, Kamdar M, Kaplan LD, Khan N, Kipps TJ, Ma S, Mato A, Mosse C, Schuster S, Siddiqi T, Stephens DM, Ujjani C, Wagner-Johnston N, Woyach JA, Ye JC, Dwyer MA, Sundar H. NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. J Natl Compr Canc Netw. 2022 Jun;20(6):622–634.

Published In

J Natl Compr Canc Netw

DOI

10.6004/jnccn.2022.0031

EISSN

1540-1413

Publication Date

June 2022

Volume

20

Issue

6

Start / End Page

622 / 634

Location

United States

Related Subject Headings

  • Proto-Oncogene Proteins c-bcl-2
  • Oncology & Carcinogenesis
  • Neoplasm, Residual
  • Lymphoma, B-Cell
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Humans
  • Antineoplastic Agents
  • 4203 Health services and systems
  • 3211 Oncology and carcinogenesis